Surface Oncology to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, where they will discuss Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surfaces emerging preclinical pipeline, highlighted by SRF813 (targeting CD112R, also known as PVRIG).